

Press Release

Georg von Hevesy-Prize 2022

Radeberg/Germany, 28th April 2022

We are pleased to announce that M.Sc. Neil Quigley has just been honored with this year's Georg von Hevesy-Prize, awarded by the German Society of Nuclear Medicine (DGN), for his outstanding contributions to the development of Ga-68-Trivehexin. Ga-68-Trivehexin is TRIMT's clinical-stage radiopharmaceutical which showed a high potential for improved diagnostics of various carcinomas by means of positron emission tomography (PET) imaging.

Together with a team of renowned researchers from the Technical University Munich, the Technical University of Dresden, and the PET Zentrum Bremen, Mr. Quigley has recently published two scientific papers that cover both the preclinical development and first successful clinical applications of Ga-68-Trivehexin. Both publications appeared in the European Journal of Nuclear Medicine and Molecular Imaging, one of the most prestigious journals in this research field (Quigley NG, et al., [ENJMMI 2021;48:4107](#) and [EJNMMI 2022;49:1136](#)).

We sincerely congratulate Mr. Quigley and the whole team to the Georg von Hevesy-Prize 2022, and wish them furthermore great success in their innovative work in the field of radiopharmaceutical sciences.

Notes to Editors

About the Georg von Hevesy-Prize

With the Georg von Hevesy-Prize, the German Society of Nuclear Medicine supports the scientists in the field of radiochemistry, radiopharmacy, and experimental nuclear medicine. The prize memorizes the Hungarian chemist Georg Karl von Hevesy (born in 1885 as Hevesy György Károly in Budapest), who established the so-called tracer principle, that is, the use of radioactive material in minuscule amounts for tracking biological processes in living subjects. His pioneering work, for which he received the Nobel Prize for Chemistry in 1943, represents the foundation of modern Nuclear Medicine and radioactivity-driven imaging methods for the rapidly growing field of precision medicine and personalized therapy.

The 2022 prize is awarded to the first author of the most important radiopharmaceutical research paper that has been published, or accepted for publication, in the previous year (2021).

About TRIMT

TRIMT GmbH is a clinical stage company developing novel radiopharmaceuticals for diagnosis as well as treatment of life-threatening diseases. The company was founded in early 2021 in Radeberg near Dresden. TRIMT holds a worldwide exclusive licence for various new radioligands based on technologies from the Technical University of Munich.

Contact

Dr. Jakub Simecek (CEO)
TRIMT GmbH
Carl-Eschbach-Str. 7
01454 Radeberg, Germany
Tel +49 (0) 3528 487 1940
www.trimt.de